Trials / Not Yet Recruiting
Not Yet RecruitingNCT06233864
A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Clinical Study of the Treatment of Disitamab Vedotin（RC48) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Expressing HER2
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 clinical study,to explore the efficacy and safety of Disitamab Vedotin in patients with locally advanced or metastatic pancreatic cancer expressing HER2.
Detailed description
63 patients with locally advanced or metastatic pancreatic cancer will participate in this study. HER2 expression in locally advanced or metastatic pancreatic cancer patients is defined as the expression of HER2 in tumor tissues detected by immunohistochemistry (IHC) as IHC 1+, 2+, or 3+. The arm 1 recruits 43 patients and the arm 2 recruits 20 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Disitamab Vedotin | Disitamab Vedotin |
| DRUG | Gemcitabine | Gemcitabine |
Timeline
- Start date
- 2024-04-17
- Primary completion
- 2025-04-17
- Completion
- 2026-04-17
- First posted
- 2024-01-31
- Last updated
- 2024-04-17
Source: ClinicalTrials.gov record NCT06233864. Inclusion in this directory is not an endorsement.